Review Article

Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis

Yongquan Tang, Zhihong Liu, Zijun Zou, Jiayu Liang, Yiping Lu, and Yuchun Zhu

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

Correspondence should be addressed to Yiping Lu; yipinglu@163.com and Yuchun Zhu; mmaalleee@126.com

Received 8 December 2017; Accepted 6 May 2018; Published 4 June 2018

Academic Editor: Hai-Feng Pan

Copyright © 2018 Yongquan Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy. We aimed to assess the prognostic benefits of adjuvant mitotane after resection of ACC in patients without distant metastasis.

Methods. The PubMed, WoS, Embase, and Cochrane Library databases were systematically searched. Recurrence-free survival (RFS) and overall survival (OS) were adopted as measurements. A meta-analysis was conducted based on hazard ratio (HR) with 95% confidence interval (CI). A study was included only if the enrolled patients underwent resection of ACC without adjuvant chemotherapy except mitotane.

Results. A total of 5 retrospective studies reporting on 1249 patients were included for this meta-analysis. The meta-analysis showed that adjuvant mitotane was significantly associated with prolonged RFS (HR = 0.62; 95% CI, 0.42-0.94; P < 0.05) and prolonged OS (HR = 0.69; 95% CI, 0.55-0.88, P < 0.05).

Conclusion. After comprehensive review, current evidence suggests that adjuvant mitotane significantly decreases the recurrence rate and mortality after resection of ACC in patients without distant metastasis, but these findings need further demonstration from prospective controlled trials.

1. Introduction

Adrenocortical carcinoma (ACC) is a malignancy characterized with much low morbidity (0.5-2/10^6) but very bad prognosis [1]. The 5-year survival rate of patients is approximately 33%-66% in stage 1 and no more than 5% in stage IV [2]. About 40%-70% of ACCs are functional [3], of which almost 80% are associated with hypersecretion of glucocorticoids (Cushing syndrome). The hypersecretion of androgen, estrogen, or aldosterone is rare [2]. Surgical resection remains the principle strategy for operable ACC, even some local advanced ACC. But the recurrence rate is up to 60%-80% without adjuvant treatment [4, 5].

In 1949, Nelson et al. initially found the adrenolytic effect of 2, 2-di(p’-chlorophenyl)-1,1-dichloroethane (2p’-DDD) in dogs [6]. Ten years later, Bergenstal et al. demonstrated the antitumor effects of 2, 2-di(o, p’-chlorophenyl)-1,1-dichloroethane (o, p’-DDD), commonly named mitotane, on functional ACC [7]. Mitotane is lipophilic and accumulates primarily in adrenal cortex and adipose tissues [8, 9]. The mechanisms of mitotane against ACC are not fully known. Some researchers found that mitotane and its metabolites could covalently bind to mitochondrial proteins to induce disruption of mitochondria, subsequently resulting in apoptosis of ACC cells [10–13]. Sbiera et al. showed that the inhibition to Sterol-O-Acyl Transferase 1 of mitotane could suppress the synthesis of cholesterol, which would induce excessive accumulation of lipids in endoplasmic reticulum, and then trigger endoplasmic reticulum stress resulting in apoptosis of ACC cells [14]. Recently, Scheidt et al. found mitotane could bind to cell membranes to destroy the membrane integrity [15]. Despite those antitumor efficacies, many patients with ACC had no response to mitotane [16], and the adverse reactions of mitotane also deserve concern. Of patients taking mitotane, approximately 50%-74% have gastrointestinal discomfort [17–19], about 38%-60% may have symptoms in neuromuscular system [17–20], and a minority may present with elevated aminotransferase or alkaline phosphatase, or reduced peripheral blood cells [18, 21]. Besides, mitotane can reduce the synthesis of corticosteroids, leading to adrenocortical insufficiency [22, 23]. Meanwhile, mitotane increases cortisol-binding proteins to reduce free cortisol.
Given the limited antitumor response and adverse reactions, the efficacy and safety of mitotane have always been in controversy. Besides, the majority of current studies have a small sample size resulting from much low incidence. In patients after tumor resection of ACC, some researchers showed that adjuvant mitotane might improve the recurrence-free survival (RFS) [29, 31], but some others got a negative result [27]. Despite that, mitotane remains the most commonly used therapeutic agent in the treatment of ACC, especially in adjuvant use. This study aimed to include all studies up to date and make a meta-analysis to assess benefit of adjuvant mitotane for postoperative prognosis in patients with ACC.

2. Materials and Methods

2.1. Search Question. Do adjuvant mitotane after resection of ACC have survival benefits for patients?

2.2. Search Strategies. The keywords “mitotane”, “survival”, and “adrenocortical carcinoma or its synonyms” were used to search in PubMed. Then Web of Science, Embase, and Cochrane Library were searched for supplementary. The search was finally updated to September 8, 2017. All records were contained in the literature pool for screening.

2.3. Studies Selection. The studies selection was performed by two reviewers independently. The titles and abstracts were firstly viewed to identify unique study enrolling ACC patients with treatment of mitotane. Case reports and nonoriginal publications including editorials, commentaries, and review articles were excluded. Then the full texts of eligible studies were reviewed. References of the selected studies were also checked to search for further eligible studies. We included randomized controlled trials and cohort studies. The studies for inclusion should have comparison of prognoses (RFS or/and overall survival [OS]) of patients with and without adjuvant mitotane after resection of ACC. A study or cohort would be excluded if the enrolled patients had distant metastases of ACC, no resection of ACC, any neoadjuvant therapy before surgery, or adjuvant chemotherapy in addition to mitotane after surgery. But adjuvant radiotherapy was allowed. We only included studies reporting adjusted hazard ratios (HR) in multivariate Cox regression and excluded unadjusted outcome measures because these may provide biased evaluations given the differences in other variates such as age, gender, adjuvant radiotherapy, etc. Duplicates in study cohort were also excluded to leave only one study with the lowest risk of bias.

2.4. Risk of Bias Assessment. We used the Newcastle-Ottawa Scale (NOS) for the quality assessment of nonrandomized controlled studies. The follow-up was considered to be adequate if it was over 5 year in median or mean time. Studies with scores $\geq 7$ were supposed to have a low risk of bias, scores of 4–6 to have a moderate risk of bias, and scores $< 4$ to have a high risk of bias [32]. The publication bias was assessed by funnel plots and Beggs's test, which was carried out in Stata 14.0 (Stata Corp, College Station, Texas, USA).

2.5. Data Extraction. The full texts were carefully reviewed by two reviewers independently. Disagreements were resolved by consensus with the senior author. We collected the following data if available:

(1) Study design and quality: publication year, country of patients, study type, patients enrolling criteria, median/maximum of follow-up, and assessed NOS score (Table 1)

(2) Multivariable factors: characteristics of cohort and potential prognostic factors adjusted for mitotane in multivariate Cox regression model, including sample size, median or mean age, proportions of male, local advanced cases (stage IV without distant metastasis), positive surgical margins, functional status, and adjuvant radiotherapy (Table 2)

(3) Outcome measures: HR of adjuvant mitotane with 95% confidence interval (CI) in RFS and OS respectively, produced by multivariate Cox progression (Table 2)

2.6. Statistical Analysis. The heterogeneity was identified by Q test, estimated by DerSimonian-Laird method and quantified by I² values [33]. Given the significant heterogeneity ($P < 0.1$ or/and $I^2 > 50\%$) for each analysis, random effects model was employed. Otherwise fixed effect model was employed. Heterogeneity test and meta-analysis were performed by the Review Manager 5.3 (Copenhagen: the Nordic Cochrane Centre, the Cochrane Collaboration, 2014) software. We used the inverse variance method for the meta-analysis of HR. The statistical differences were assessed by Z test. The difference was significant given the $P < 0.05$.

3. Results

3.1. Description of Included Studies. Our literature searching identified 324 records. After full-text review of 42 unique studies, 5 studies were included for meta-analysis. The reasons for exclusion are provided in Figure 1. The detail characteristics of these studies were provided in Table 1. All included studies provided adjusted HR with 95%CI between adjuvant mitotane and nonmitotane in RFS or/and OS. All enrolled patients had resection of ACC without other chemotherapy in addition to mitotane. Patients were enrolled from 1979 to 2014. Overall, 1249 patients were included in the meta-analysis, of which 408 patients (33%) received adjuvant mitotane, 32%-39% were male, and 43%-55% had hormone secreting ACC. Median age was 43-51 years old. Three studies enrolled patients with local advanced ACC (4%-31%) [16, 27, 29]. Three studies provided exact numbers of enrolled patients with positive surgical margins (0%-31%) [27, 29, 30]. And two studies declared that patients with adjuvant radiotherapy were allowed [27, 30] (Table 2).
| Reference | Year | Country | Inclusion criteria<sup>a</sup> | Follow-up<sup>b</sup> | Adjusting factors<sup>c</sup> | NOS |
|-----------|------|---------|-------------------------------|-----------------|--------------------------|-----|
| Berruti [16] | 2017 | Italy | 1985-2003 ≥ 18 years old R0, R1 Stage I-IV | >128/>200 months | Age Gender Stage | 8 |
| | | | No radiotherapy 1993-2014 | | Age | 7 |
| Postlewait [27] | 2016 | USA | 1993-2014 R0, R1, R2 Stage I-IV | 44/>60 months | Age Gender Function Stage | 7 |
| | | | Allowed radiotherapy | | Surgical margins Radiotherapy et al. | |
| Berruti [28] | 2014 | Italy, Germany, Holland, France, USA | 1990-2008 ≥ 18 years old R0 Stage I-IV | 50/>120 months | Age Gender Function Stage | 7 |
| | | | Allowed radiotherapy | | | |
| Grubbs [29] | 2010 | USA | 1991-2008 R0, R1, Rx Stage I-IV | 88/>300 Months | Age Gender Function Stage | 8 |
| | | | Allowed radiotherapy 1990-2009 | | Surgical margins Mitotic count | |
| Fassnacht [30] | 2010 | Germany | 1990-2009 R0, R1, R2, Rx Stage II | 38/>60 months | | 7 |

<sup>a</sup> R0 denotes microscopically negative margin; R1 denotes microscopically positive margin; R2 denotes grossly positive margin.

<sup>b</sup> Median/maximum length of follow-up.

<sup>c</sup> Prognostic factors adjusted for mitotane in multivariate Cox regression model.
Table 2: Characteristics of patients and hazard ratios (HR) (95% confidence interval [95%CI]) of mitotane in multivariate Cox regression model fitted for time of recurrence-free survival (RFS) and overall survival (OS), adjusted by age, gender, stage, positive surgical margins (PSMs), functional status and/or adjuvant radiation, etc.

| Reference   | Year | Total No. | Age/y\(^a\) | Male/% | Stage IV/%\(^b\) | PSMs/%\(^c\) | Function/% | Radiation/% | Mitotane\(^d\) | RFS/HR(95%CI)\(^e\) | OS /HR(95%CI)\(^f\) |
|-------------|------|-----------|--------------|--------|------------------|-------------|------------|-------------|----------------|---------------------|---------------------|
| Berruti [16]| 2017 | 92        | 43           | 32     | 11               | -           | 45         | 0           | 47             | 1/2.98(1.75-5.09)   | 1/2.03(1.17-3.51)   |
| Postlewaıt [27]| 2016 | 169\(^g\) | 51           | 39     | 31               | 31          | 43         | 10          | 56             | 1.4(0.8-2.4)        | 0.7(0.3-1.5)        |
| Berruti [28] | 2014 | 524       | 45           | 39     | 0                | 0           | 52         | -           | 251            | 0.66(0.53-0.83)     | 0.82(0.60-1.10)     |
| Grubbs [29]  | 2010 | 215       | 46           | 35     | 4                | 27          | 55         | -           | 19             | 1/1.96(1.07-3.61)   | 1/1.58(0.75-3.31)   |
| Fassnacht [30]| 2010 | 149       | 48           | 35     | 0                | 9           | -          | 9           | 35             | 0.58(0.29-1.15)     | 0.38(0.12-1.28)     |

\(^a\)Median or mean age of total population.
\(^b\)Local advanced cases without distant metastasis.
\(^c\)(R1+R2) / (R0+R1+R2) (R0 denotes microscopically negative margin; R1 denotes microscopically positive margin; R2 denotes grossly positive margin) in spite of R0 or data loss.
\(^d\)Number of patients who received mitotane.
\(^e\)HR of mitotane relative to nonmitotane. When a study provided HR of no mitotane relative to mitotane, it was recorded as 1/HR.
Among them, the study of Berruti et al. (2017) had 2 independent control groups enrolling Italian (n = 45) and German (n = 70), respectively, relative to a shared mitotane group (n = 47) [16]. The German group was excluded since the patients have been reported before by Fassnacht in the same center (University Hospital of Würzburg, Germany) [30].

3.2. Risk of Bias. All included studies were assessed to have a low risk of bias (NOS score ≥ 7) (Table 1). Especially, publication bias of outcomes was not significant (P > 0.05) according to Begg's test.

3.3. Recurrence-Free Survival and Overall Survival. In total, 5 studies reporting on 1249 patients were included to assess the effect of adjuvant mitotane on RFS. The heterogeneity of outcomes was significant (P = 0.01, I² = 71%). So the random effects model was employed. As a result, adjuvant mitotane was significantly associated with prolonged RFS (HR = 0.62; 95%CI, 0.42-0.94, P = 0.02) (Figure 2). The same crews of studies were included to assess the effect of adjuvant mitotane on OS. There was no evidence of significant heterogeneity among these studies (P = 0.45, I² = 0%). So fixed effect model was employed. As a result, adjuvant mitotane was significantly associated with prolonged OS (HR = 0.69; 95%CI, 0.55-0.88, and P < 0.01) (Figure 3).

4. Discussion

This review and meta-analysis identified that adjuvant mitotane was significantly associated with prolonged RFS and OS after resection of ACC in patients without distant metastasis. It indicates that adjuvant mitotane tends to reduce 38% of postoperative recurrences and 31% of postoperative deaths.
To the best of our knowledge, this study represents the first meta-analysis and most up-to-date reviews on this topic. There were some evidence reviews before on adjuvant use of mitotane. Veytsman et al. claimed that adjuvant mitotane remained controversial although most clinicians agreed that adjuvant mitotane should be used given a high likelihood of recurrence [34]. Campbell-Walsh Urology, 10th Edition, read that few studies demonstrated a significant survival benefit from mitotane as a single agent [2]. Terzolo et al. also did not provide a definite recommendation referring to 3 retrospective studies [35]. All these reviews were limited by few references and lacking meta-analysis of outcomes.

The major strengths of this meta-analysis include systematic search strategies, careful studies selection and data extraction, critical bias assessment, and feasible statistical method. Both NOS and Beggs’s test indicated that these included studies had a low risk of bias. The age, gender, and functional status among these included studies were very similar (Table 2). Although we found statistically significant heterogeneity of outcomes for RFS analysis, random effects model was employed. Influence-analysis found that Postlewait, 2016 predominated in the heterogeneity. This likely resulted from small cohort size with much more differences in other factors like functional status, stage, postoperative adrenal insufficiency, adjuvant radiotherapy, etc. [27]. Actually, 7 studies were eligible for our aims, but two of them were excluded for duplicating report. Terzolo had the same cohorts with Berruti (2017), and the former was excluded since its shorter follow-up [16, 31]; Berruti (2014) had two common participating centers with Berruti (2017), but it declared that patients included in this study had not been included in the study of Terzolo that had the same cohorts with Berruti (2017) [16, 28]. The study of Else enrolled patients in University of Michigan Hospital from 1979 to 2013, which have been reported by Berruti (2014), and the former was excluded since its smaller sample size [28, 36].

A key limitation is that this meta-analysis is primarily based on retrospective studies, since no fully prospective controlled study is available to our knowledge. So potential biases deserved concerns on selection bias, lost to follow-up, confounding factors, and reporting bias etc. Firstly, it is known that adjuvant mitotane tended to be used in patients with a high likelihood of recurrence [34] given infiltration out of adrenal, local lymph nodes metastasis, and/or positive surgical margins, which may produce selection bias in each study. Despite that, the RFS and OS in mitotane cohort were still significantly superior to that in nonmitotane cohort, which provided further support to our findings. Secondly, Kaplan-Meier survival rate curve could largely reduce bias of loss, and all included studies had follow-up over 5 years if not death or loss. Thirdly, positive surgical margins and adjuvant radiotherapy may be potential confounding factors. Postlewait et al. said that both microscopically and macroscopically positive margins were significantly independent risk factors for OS [27]. But several studies revealed that adjuvant radiotherapy was not associated with RFS and OS in adjusted HR analysis [27, 36, 37]. Although we were not able to make subgroup analysis to explore these two potential confounding factors since insufficient data, all extracted HR with 95%CI have been adjusted to other potential prognostic factors in multivariate Cox regression. The salvage treatment after recurrence was another potential...
prognostic factor for OS. Three studies declared that patients received salvage surgery, radiotherapy, and/or chemotherapy after recurrence, but all of them did not consider it as an adjusting factor [16, 27, 30]. However, all patients in a certain center or country were generally managed following common criteria despite whether a patient received adjuvant mitotane or not. In addition, some other researchers indicated that maintenance of mitotane concentrations ≥ 14 mg/L was significantly associated with RFS benefit [38]. But plasma level of mitotane was rarely revealed in these included studies, most likely because few data were available [27, 36]. Fourth, postoperative death was not clearly defined either by ACC or all-course death by authors except Fassnacht et al. [27]. To reduce this bias, Berruti et al. (2017) excluded patients with clinically significant concomitant diseases [16]. Towards benefit for patients, it is obvious that RFS and OS cannot represent all. Regarding potential side effects, the quality-of-life during adjuvant mitotane should be considered, but no study has assessed it. While generally, most clinicians agreed that mitotane was used only if well tolerated [39].

Briefly, this study provides very comprehensive evidences, and most potential biases were controlled. Therefore we recommend adjuvant use of mitotane after resection of ACC if well tolerated, because adjuvant mitotane was associated with significantly prolonged RFS and OS on these patients.

5. Conclusion

Mainly based on retrospective cohort studies, this meta-analysis suggests that adjuvant mitotane significantly decreases recurrence rate and mortality after resection of ACC in patients without distant metastasis, but this finding needs further demonstration from prospective controlled trials.

Additional Points

A key publication error in an included study was confirmed by its corresponding author (Maithel, S. K.) that “adjuvant chemotherapy” in last row of the table in page 8 should actually be read “mitotane.”

Conflicts of Interest

All the authors declare that they have no any conflicts of interest.

Authors’ Contributions

Yongquan Tang and Zhihong Liu contributed equally to this study.

Acknowledgments

This study is funded by the Department of Science and Technology of Sichuan Province, China (Grant no. 2017SZ0123), and 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.

References

[1] S. Keskin, F. Taş, and S. Vatansver, “Adrenocortical carcinoma: Clinicopathological features, prognostic factors and outcome,” Urologia Internationalis, vol. 90, no. 4, pp. 435–438, 2013.
[2] Elsevier, Campbell-Walsh Urology, Saunders Press, Philadelphia, PA, USA, 10th edition, 2012.
[3] M. D. Wooten and D. K. King, “Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature,” Cancer, vol. 72, no. 11, pp. 3145–3155, 1993.
[4] A. Stojadinovic, R. A. Ghosein, A. Hoos et al., “Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization,” Journal of Clinical Oncology, vol. 20, no. 4, pp. 941–950, 2002.
[5] A. Meyer and M. Behrend, “Long-term survival over 28 years of a patient with metastatic adrenal cortical carcinoma - Case report,” Anticancer Research, vol. 24, no. 3B, pp. 1901–1904, 2004.
[6] A. A. Nelson and G. Woodward, “Severe adrenal cortical atrophy (cystotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE),” Archives of Pathology, vol. 48, pp. 387–394, 1949.
[7] D. M. Bergenstal, R. Hertz, M. B. Lipsett, and R. H. Moy, “Chemotherapy of adrenocortical cancer with O,P-DDE,” Annals of Internal Medicine, vol. 53, pp. 218–221, 1960.
[8] J. W. Latimer and H. S. Siegel, “DDT and metabolite accumulation in adrenal, liver, and brain of broiler chickens,” POULTRY SCI., vol. 56, no. 5, pp. 1622–1626, 1977.
[9] B.-O. Lund, Å. Bergman, and I. Brandt, “Metabolic activation and toxicity of a DDT-metabolite, 3-methylsulphonyl-DDE, in the adrenal Zona fasciculata in mice,” Chemico-Biological Interactions, vol. 65, no. 1, pp. 25–40, 1988.
[10] J. Jönsson, H. Rodriguez-Martinez, and I. Brandt, “Transplacental toxicity of 3-methylsulphonyl-DDE in the developing adrenal cortex in mice,” Reproductive Toxicology, vol. 9, no. 3, pp. 257–264, 1995.
[11] C.-J. Jönsson, H. Rodriguez-Martinez, B.-O. Lund, Å. Bergman, and I. Brandt, “Adrenocortical toxicity of 3-methylsulfonyl-DDE in mice. II. Mitochondrial changes following ecologically relevant doses,” Fundamental and Applied Toxicology, vol. 16, no. 2, pp. 365–374, 1991.
[12] V. Asp, V. Lindström, J. A. Olsson, U. Bergström, and I. Brandt, “Cytotoxicity and decreased corticosterone production in adrenocortical Y-1 cells by 3-methylsulfonyl-DDE and structurally related molecules,” Archives of Toxicology, vol. 83, no. 4, pp. 389–396, 2009.
[13] G. Poli, D. Guasti, E. Rapizzi et al., “Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells,” Endocrine-Related Cancer, vol. 20, no. 4, pp. 537–550, 2013.
[14] S. Sbiera, E. Leich, G. Liebisch et al., “Mitotane inhibits sterol-O-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells,” Endocrinology, vol. 156, no. 11, pp. 3895–3908, 2015.
[15] H. A. Scheidt, I. Haralampiev, S. Theisgen et al., “The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition,” Molecular and Cellular Endocrinology, vol. 428, pp. 68–81, 2016.
[16] A. Berruti, S. Grisanti, A. Pulzer et al., “Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma,” The Journal of Clinical Endocrinology & Metabolism, vol. 102, no. 4, pp. 1365–1369, 2017.

[17] J. A. Lubitz, L. Freeman, and R. Okun, “Mitotane use in Inoperable Adrenal Cortical Carcinoma,” Journal of the American Medical Association, vol. 223, no. 10, pp. 1099–1112, 1973.

[18] F. Daffara, S. de Francia, G. Reimondo et al., “Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly,” Endocrine-Related Cancer, vol. 15, no. 4, pp. 1043–1053, 2008.

[19] D. Maiter, M. Bex, L. Vroonen et al., “Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients,” Annales d’Endocrinologie, vol. 77, no. 5, pp. 578–585, 2016.

[20] H. Du Rostu, M. Krempf, and J. M. Mussini, “Neurotoxicity of mitotane treatment of adrenocortical carcinoma (5 cases) and Cushing’s syndrome (7 cases),” La Presse Médicale, vol. 16, no. 19, pp. 951–954, 1987.

[21] A. A. Kasperlik-Zaluska, “Clinical results of the use of mitotane for adrenocortical carcinoma,” Brazilian Journal of Medical and Biological Research, vol. 33, no. 10, pp. 1191–1196, 2000.

[22] D. E. Schteingart, J. E. Counsell et al., “Comparison of the adrenolytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 31, no. 6, pp. 459–466, 1993.

[23] J. T. Sanderson, J. Boerma, G. W. A. Lansbergen, and M. Van Den Berg, “Induction and inhibition of aromatase (CYP19) activity by various classes of pesticides in H295R human adrenocortical cancer cells,” Toxicology and Applied Pharmacology, vol. 182, no. 1, pp. 44–54, 2002.

[24] V. Chortis, A. J. Moolenaar, and P. Schneider, “Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase,” explaining the need for personalized glucocorticoid and androgen replacement. The journal of clinical endocrinology and metabolism 98, pp. 161–171, 2013.

[25] A. P. Van Seters and A. J. Moelenaar, “Mitotane increases the blood levels of hormone-binding proteins,” Acta Endocrinologica, vol. 124, no. 5, pp. 526–533, 1991.

[26] D. L. Reidy-Lagunes, B. Lung, B. R. Uicht et al., “Complete responses to mitotane in metastatic adrenocortical carcinoma—A new look at an old drug,” The Oncologist, vol. 22, no. 9, pp. 1102–1106, 2017.

[27] L. M. Postlewait, C. G. Ethun, T. B. Tran et al., “Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group,” Journal of the American College of Surgeons, vol. 222, no. 4, pp. 480–490, 2016.

[28] A. Berruti, M. Fassnacht, H. Haak et al., “Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer,” European Urology, vol. 65, no. 4, pp. 832–838, 2014.

[29] E. G. Grubbs, G. G. Callender, Y. Xing et al., “Recurrence of adrenal cortical carcinoma following resection: Surgery alone can achieve results equal to surgery plus mitotane,” Annals of Surgical Oncology, vol. 17, no. 1, pp. 263–270, 2010.

[30] M. Fassnacht, S. Johansson, W. Fenske et al., “Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 11, pp. 4925–4932, 2010.

[31] M. Terzolo, A. Angeli, M. Fassnacht et al., “Adjunctive mitotane treatment for adrenocortical carcinoma,” The New England Journal of Medicine, vol. 356, no. 23, pp. 2372–2380, 2007.

[32] G. A. Wells, B. J. Shea, D. O’Connell et al., “The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis,” Applied Engineering in Agriculture, vol. 18, pp. 727–734, 2014.

[33] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003.

[34] I. Veytsman, L. Nieman, and T. Fojo, “Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma,” Journal of Clinical Oncology, vol. 27, no. 27, pp. 4619–4629, 2009.

[35] M. Terzolo and A. Berruti, “Adjunctive treatment of adrenocortical carcinoma,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 15, no. 3, pp. 221–226, 2008.

[36] J. A. Lubitz, L. Freeman, and R. Okun, “Mitotane use in Inoperable Adrenal Cortical Carcinoma,” Journal of the American Medical Association, vol. 223, no. 10, pp. 1099–1112, 1973.